14 research outputs found
THE BIOAVAILABILITY OF TAMOPLEX (TAMOXIFEN) .3. A STEADY-STATE STUDY IN BREAST-CANCER PATIENTS
No full textSERUM ELIMINATION HALF-LIFE OF TAMOXIFEN AND ITS METABOLITES IN PATIENTS WITH ADVANCED BREAST-CANCER
No full textSerum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels
No full textTHE BIOAVAILABILITY OF TAMOPLEX (TAMOXIFEN) .3. A STEADY-STATE STUDY IN BREAST-CANCER PATIENTS
No full textSERUM ELIMINATION HALF-LIFE OF TAMOXIFEN AND ITS METABOLITES IN PATIENTS WITH ADVANCED BREAST-CANCER
No full textSERUM ELIMINATION HALF-LIFE OF TAMOXIFEN AND ITS METABOLITES IN PATIENTS WITH ADVANCED BREAST-CANCER
No full textIs platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?
No full textObjective: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. Study Design: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. Results: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the Is patients with a tumorrest >2 cm, then was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest less than or equal to2 cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95% CI 0.4-1.9)). Conclusion: We could not show that ovarian cancer patients with residual disease of less than or equal to2 cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.</p
NEW INSIGHTS INTO THE TAMOXIFEN PHARMACOKINETICS CONSTITUTE A BASIS FOR A LOADING DOSE SCHEME
No full textNEW INSIGHTS INTO THE TAMOXIFEN PHARMACOKINETICS CONSTITUTE A BASIS FOR A LOADING DOSE SCHEME
No full textIs platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?
No full textObjective: Suboptimally debulked patients with advanced ovarian cancer who are treated with a combination of cisplatin plus paclitaxel (TP therapy) have a better survival as compared to patients treated with a combination of cisplatin plus cyclophosphamide (CP therapy), but this advantage has not been demonstrated in optimally debulked patients. We performed a retrospective study to compare the effectiveness of TP therapy and CP therapy in optimally debulked patients. Study Design: From 1991 to 1996, 87 consecutive patients with advanced ovarian cancer treated in the University Hospital Utrecht and the St. Antonius Hospital were included in the study. Overall survival (OS) of patients treated with TP or CP were compared. Multivariable Cox-regression analysis was used to calculate a hazard rate ratio (HRR) for OS. Results: In the study period, 51 patients were treated with CP, and 36 patients were treated with TP. In the Is patients with a tumorrest >2 cm, then was a clear, but not statistically significant benefit from TP. In 69 patients with a tumorrest less than or equal to2 cm, life expectancy was not increased in patients treated with TP as compared to patients treated with CP (HRR 0.9 (95% CI 0.4-1.9)). Conclusion: We could not show that ovarian cancer patients with residual disease of less than or equal to2 cm who were treated with TP had better survival as compared to patients who were treated with CP. Taking into account the high costs of treatment with TP, a randomized trial comparing the effects of TP therapy and CP therapy in optimally debulked patients is warranted. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved
